Sedigheh Gholami1,2, Zahra Mazidi1, Sara Pahlavan1, Fariba Moslem1, Mahya Hosseini1, Adeleh Taei1, Mahdi Hesaraki1, Maryam Barekat3, Nasser Aghdami4, Hossein Baharvand5,2. 1. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. 2. Department of Developmental Biology, University of Science and Culture, Tehran, Iran. 3. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. 4. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. Email: nasser.aghdami@royaninstitute.org. 5. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. Email: baharvand@royaninstitute.org.
Systemic sclerosis (SSc) develops as a chronic
connective tissue disease which involves multiple organs;
however, its etiology remains unknown. It is characterized
by vascular injury, immune dysregulation and extensive
fibrosis of several organs including the skin (1). The
complex pathogenesis of SSc remains unclear, however
it is known that genetic, epigenetic and environmental
factors contribute to its development (2). Endothelial cell
(EC) injury is one of the first phases in pathogenesis of
SSc. The damaged endothelium upregulates the expression
of adhesion molecules and chemokines resulting in
recruitment of inflammatory cells. Multiple cytokines and
growth factors, secreted by inflammatory and immune
cells, promote activation and differentiation of resident
fibroblasts into myofibroblasts, which cause excessive
extracellular matrix (ECM) proteins production leading
to fibrosis. Thus, suggested pathogenesis of SSc includes
a complex interplay between vascular abnormality,
inflammation and autoimmunity, as well as fibrosis (3).Clinical and in vitro studies demonstrated an impaired angiogenesis in
SSc. Moreover, several studies suggested that ECs might be the origin of a subset of
activated fibroblasts or myofibroblasts. Furthermore, endothelial-mesenchymal transition
(EndoMT) and their differentiation into collagen-producing cells are likely to represent an
additional source of extra collagen (4).In addition to vascular complications, many cases
of heart phenotypes have been reported in SSc which
accounts for 11-36% mortality in these patients (5).
Cardiac manifestation of SSc can be caused directlyby a myocardial involvement developing to myocardial fibrosis or indirectly by pulmonary
arterial hypertension or systemic hypertension as the possible outcome of pulmonary and
renal involvements (6). Not only the heart wall including epicardium, myocardium and
endocardium, but also coronary arteries, cardiac valves and nervous system may be
affected in SSc leading to heart failure (7). A meta-analysis done by Komócsi et al. (8),
confirmed that cardiopulmonary manifestation is the main cause of mortality in SSc patients.
Despite cohort studies suggesting a decline in mortality risk of SSc, a meta-analysis of
cohort studies, conducted by Elhai et al. (9) reported no substantial changes in
standardized mortality ratio (SMR) over 40 years.Over the last decade, molecular studies-based clinical
trials provided more knowledge on the pathogenesis of
scleroderma (10), however, further investigations are
still needed. Such molecular studies require appropriate
animal or cell-based models recapitulating scleroderma
phenotype. Patient-specific induced pluripotent stem cells
(iPSCs) allow us to examine the disease phenotype in
target tissue as well as other cell types of body (11). In
the present study, we produced iPSC from skin biopsies
of two SSc patients and characterized them followed by
cardiogenic differentiation into cardiomyocytes (CMs)
and ECs and their characterization.
Materials and Methods
Generation of patient-specific induced pluripotent
stem cells
In this experimental study, human dermal fibroblasts of SSc patients were digested using
0.1% collagenase I (Sigma, USA) and cultured in fibroblast medium (Dulbecco’s modified
Eagle’s medium [DMEM, Gibco, USA]) enriched with 10% fetal bovine serum (FBS, Gibco, USA)
and 1% penicillin and streptomycin (Gibco, USA), as previously described (12).
Institutional review board approval by Royan Institute Ethics Committee’s general
principles in compliance with the declaration of Helsinki (IR ACECR, ROYAN REC, 1395 175)
and consent from patients for iPSC derivation, were obtained. The clinical features of the
SSc patients are shown in Table S1 (See Supplementary Online Information at www.
celljournal.org). To generate patient-specific iPSC, dermal fibroblasts were reprogrammed
by four Yamanaka factors (OCT4, SOX2, KLF4, and c-MYC)
delivered by retrovirus in serum- and feeder-free conditions based on a previously
reported protocol (12). On transduction day 6, fibroblast medium was exchanged with human
embryonic stem cell (hESC) medium supplemented with 100 ng/ml basic fibroblast growth
factor (bFGF, Royan Biotech, Iran). hESC medium was comprised of DMEM/F12
(Gibco, USA) supplemented with 20% Knockout serum replacement (KOSR, Gibco, USA), 1%
non-essential amino acids (Gibco, USA), 1% penicillin and streptomycin, 2 mM L-glutamine
(Gibco, USA) and 0.1 mM β-mercaptoethanol (Sigma, USA). At day 14-20 of re-plating,
embryonic stem cells (ES)- like colonies were observed (Fig.1A). For each patient, three
iPSC clones were established for subsequent analyses. Due to same characteristics, we
followed our experiment on one clone for each patient. Two control iPSC lines, one derived
from a healthy Iranian 40-year-old male (iPSC4 abbreviated as C1) (12) and the other
obtained from a healthy Iranian 32-year-old female (B-iPSC11 abbreviated as C2) (13) were
acquired from the Stem Cell Bank of Royan Institute. Following thawing, iPSC was cultured
on mitomycin C-treated mouse embryonic fibroblast (MEF) feeder cells in hESC medium
supplemented with 5 ng/ml bFGF. For expansion, iPSCs were passaged on ECM Gel (Sigma, USA,
1:30) using collagenase IV (0.5 mg/ml, Gibco, USA): dispase (1 mg/ml, Gibco, USA) at the
ratio of 1:2.
Fig.1
Characterization of established SSc iPSC. A. Phase contrast microscopy of
established SSc iPSC clones [S1-iPS2 (patient 1) and S2-iPS3 (patient 2)] and ALP
staining of derived iPSC (scale bar: 200 µm), B. Immunofluorescence
staining demonstrated the expression of pluripotency markers (OCT4, NANOG, TRA-1-60
and TRA-1-81) in derived iPSC. Nuclei were counterstained with DAPI (scale bar: 100
µm), C. Both S1-iPS2 and S2-iPS3 lines maintained normal karyotype,
D. qRT-PCR analysis showed endogenous OCT4 and
NANOG expression in SSc iPSC to levels similar to those of healthy
control-iPSC (C1-iPSC) while were silent in the HDF. Fold change was calculated by
∆∆Ct method and expression of each gene was normalized against GAPDH,
E. RT-PCR analyses indicated the expression of differentiation markers
for the three germ layers by EB-mediated differentiation (Diff) in comparison with
undifferentiated state (Un), and F. Tissue morphology of teratoma derived
from SSc iPSC (scale bar: 100 µm). Data are represented as mean ± SEM, n=3 (biological
replicate). SSc; Systemic sclerosis, iPSC; Induced pluripotent stem cells, ALP;
Alkaline phosphatase, qRT-PCR; Quantitative real-time polymerase chain reaction, HDF;
Human dermal fibroblasts, and EB; Embryoid body.
Karyotype analysis
Karyotyping was performed at cytogenetic laboratory
of the Institute for Human Genetics (Royan Institute,
Iran) according to a standard procedure described
previously (14). Briefly, 70% confluent human iPSC
(hiPSC) colonies were treated with 0.66 µM thymidine
(Sigma-Aldrich, USA) at 37˚C overnight. Then, cells
were washed and rested for 5 hours before being exposed
to colcemid (Gibco, USA, 0.15 µg/ml) for 30 minutes.
Afterwards, trypsinized cells were treated with 0.075 M
KCl and fixed. Karyotyping was performed using standard
G-band staining.
In vitro spontaneous differentiation of human induced pluripotent
stem cells
To evaluate the spontaneous differentiation capacity of
the above-noted derived hiPSC lines into three embryonic
germ layers, we generated embryoid body (EB). Briefly,
hiPSC colonies were dispersed into single cells using
Accutase (Sigma, USA) and transferred into non-adhesive
bacterial plates (Greiner Bio-One, Germany) containing
DMEM/F12 medium supplemented with 20% KOSR, 1%
non-essential amino acids, 2 mM L-glutamine, and 0.1
mM β-mercaptoethanol without bFGF. After 12 days, the
generated EBs were plated on ECM Gel-coated culture
dishes for another 8 days. On day 21 of spontaneous
differentiation, EB samples were collected and ectoderm,
mesoderm and endoderm differentiation were evaluated
with respect to transcriptional expression of each germ
layer’s specific genes using quantitative real-time
polymerase chain reaction (qRT-PCR).
Teratoma formation
Sc iPSC (2×106) were suspended in phosphate-buffered saline (PBS) and
injected into the subrenal capsule of 8-week-old NOD/SCID mice (BioLASCO) using a 26-gauge
syringe (BD Biosciences, USA). Eight weeks after injection, tumors were harvested, weighed
and fixed in 10% formalin. After fixation, tumors underwent histological analyses for
ectoderm, mesoderm and endoderm formation.
Immunofluorescence and alkaline phosphatase
staining
Cells were fixed in 4% paraformaldehyde at room
temperature (RT) for 25 minutes, washed with PBS/0.05%
Tween 20 and permeabilized using 0.5% Triton X-100 in
PBS for 30 minutes at RT. Thereafter, cells were washed
and blocked in blocking solution (1% bovine serum
albumin [BSA, Life Technology] in PBS) for 1 hour at
RT. Primary antibodies were diluted in blocking solution
and added to the cells overnight at 4˚C. Cells were then
washed three times with PBS/0.05% Tween 20, each time
for 5 minutes, and incubated with appropriate secondary
antibodies in blocking solution for 45 minutes at RT. Lastly,
cells were washed three times with PBS/0.05% Tween
20 and nuclei were counterstained with 4’,6-diamino-2-
phenylindole (DAPI, Sigma, USA). Images were captured
using a fluorescent microscope (IX71, Olympus, Japan).
Antibodies used in the present study are mentioned in
Table S2 (See Supplementary Online Information at
www.celljournal.org).We performed Alkaline phosphatase (ALP) staining
based on the manufacturer’s instructions (Sigma, USA).
Cardiac and endothelial differentiation of human
induced pluripotent stem cells
hiPSC colonies were dispersed into single cells by 4-5 minutes treatment with Accutase
(Sigma-Aldrich, USA) at 37˚C and incubated in non-adhesive bacterial plates (Greiner
Bio-One, Germany) at the density of 2×105 cells/ml in hESC medium. After
aggregate formation, the directed cardiogenic differentiation of hiPSC was performed in
static suspension culture using a cocktail of small molecules (SM) as previously described
(15). Briefly, hiPSC aggregates with average diameter of 175 ± 25 μm were treated with 12
μM of SM CHIR99021 (CHIR, Stemgent, USA) in differentiation medium (RPMI 1640 (Gibco, USA)
supplemented with 2% B27 without retinoic acid (Gibco, USA), 2 mM L-glutamine (Gibco,
USA), 0.1 mM β-mercaptoethanol (Sigma, USA), 1% nonessential amino acids (Gibco, USA), 1%
penicillin and streptomycin). After 24 hours, aggregates were washed with Dulbecco’s PBS
(DPBS, Gibco, USA) and maintained in fresh differentiation medium for 24 hours. On
differentiation day 2, the medium was changed with new differentiation medium containing 5
μM IWP2 (Tocris Bioscience, UK), 5 μM SB431542 (Sigma-Aldrich, USA) and 5 μM purmorphamine
(Pur, Stemgent, USA) for 48 hours. On day 4, the aggregates were washed with DPBS and
cultured in fresh differentiation medium which was refreshed every 2 or 3 days. In order
to determine the efficiency of cardiac differentiation, we counted the number of beating
spheroids on a daily basis, starting with the first beating observation, using an inverted
cell culture microscope (Olympus, Japan). For CM immunostaining, the
30-day-post-differentiation beating spheroids were subjected to enzymatic digestion by 4-5
min treatment with Accutase at 37˚C followed by gentle pipetting and plated at the density
of 8×104 cell/ cm2 on ECM-Gel (Sigma, USA, 1:30) coated 4-well
tissue-culture plate in differentiation medium. After adequate cell attachment, CM were
fixed and all steps of immunofluorescence staining were taken as described in
supplementary material.For endothelial differentiation, we used a previously reported protocol with some
modifications (16). hiPSC aggregates with average diameter of 200-250 µm were treated with
12 µM of CHIR99021 in RPMI medium supplemented with B27 without retinoic acid for 24
hours. Cells were then incubated in RPMI/B27 without SM for another 24 hours. On day 2 of
differentiation, cells were treated with 25 ng/ml BMP4 (R&D), 10 µM Purmorphamine, 10
µM SB431542 and 50 ng/ml VEGF-A (Royan-Biotech, Iran) in RPMI/B27 medium for 48 hours.
Next, the medium was exchanged with EGM-2 (Lonza, Switzerland) supplemented with 50 ng/ ml
VEGF-A and cells were incubated for another 48 hours. On day 6, differentiated aggregates
were dispersed into singles cells using Accutase and sorted based on KDR expression
(R&D, USA). KDR+ sorted cells were sub-cultured on collagen type I-coated
plates (10 μg/cm2, Sigma-Aldrich, USA) in EGM-2 medium containing 50 ng/ml
VEGF-A until reaching appropriate confluency
Gene expression analyses
Total RNA was extracted using TRIzol reagent (Sigma-Aldrich, USA). Toprevent DNA
contamination, extracted RNA was treated with RNase-free DNase I (Takara, Japan). cDNA
synthesis was performed using a PrimeScriptTM RT Reagent Kit (Perfect Real
Time) (Takara, Japan) based on the manufacturer’s instructions and qRT-PCR was performed
using a SYBR Premix Ex Taq Kit (Takara Bio. Inc, Japan) and a Rotor Gene Corbett System
(Corbett Life Science, Australia). Results were analyzed by Rotor-Gene 6000 analysis
software (Corbett Life Science, Australia, version 1.7). All experiments were done in
triplicate. The relative gene expression level of the desired genes was calculated by ∆∆CT
method and normalized against the housekeeping gene, glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). All primer sequences used in the present work, are
listed in Table S3 (See Supplementary Online Information at www.celljournal.org).
Flow cytometry and cell sorting
Differentiated hiPSC aggregates were collected at
particular time-points of differentiation and dissociated
into single cells using Accutase solution and 0.05%
trypsin/ ethylenediaminetetracetic acid (Gibco, USA)
for hiPSC-CM and hiPSC-EC, respectively. Then, single
cells were fixed by treatment with 4% paraformaldehyde
for 20 minutes at 4˚C. After washing with PBS/0.05%
Tween 20, the fixed cells were permeabilized by 0.2%
Triton X-100 in PBS for 30 minutes at RT, blocked in
serum and stained, either 1 hour for surface markers or
overnight for cytoplasmic markers, with appropriate
primary antibodies at 4˚C. Cells were then washed and incubated with appropriate secondary antibody for 1 hour
at RT. Cells were analyzed using a BD FACS Calibur flow
cytometer (BD Biosciences, USA). Data analysis was
done by Flowing Software (version 2.5.1, Turku Centre
for Biotechnology, Finland).For sorting, cells were dissociated into single cells
using 0.05% trypsin/EDTA on day 6 of endothelial
differentiation. Cells were then washed in PBS containing
2% FBS (FACS buffer) and incubated with anti-human
KDR for 1 hour at 4˚C. After washing, KDR-positive
cells were sorted using FACS Calibur.
Uptake of acetylated low-density lipoprotein (Dil-ac-LDL
ECs were incubated with 10 µg/ml of acetylated low-density lipoprotein (Dil-Ac-LDL, Biomedical Technology,
UK) for 4 hours at 37˚C. Then, cells were fixed by
treatment with 4% paraformaldehyde for 10 minutes at
RT. After washing with PBS, nuclei were counterstained
with DAPI (DAPI, Sigma, USA) and visualized using a
fluorescence microscopy (IX71; Olympus, Japan).
Tube formation assay
ECMatrix™ (In Vitro Angiogenesis Assay Kit, Chemicon, USA) was aliquoted into all wells
of a 96-well plate (50 µl/well) and incubated for 1-2 hour at 37˚C to polymerize.
Thereafter, 104 cells/well were seeded onto the matrix in 150 μl of EGM-2
medium and incubated for 2 hours at 37˚C with 5% CO2 . Tube formation was
assessed using Olympus CKX41 inverted microscope and analyzed using “Image J”
software.
Multielectrode array recording
A multielectrode array (MEA) data acquisition system (Multi Channel Systems, Reutlingen,
Germany) was used to record the extracellular field potential (FP) of hiPSC-CM. The MEA
plate is composed of 60 titanium nitride electrodes with an inter-electrode space of 200
µm. Beating spheroids were plated on ECM Gel-coated MEA plates and allowed to attach for
48-72 hours before recording. Baseline FP recording and drug testing were performed 30 ± 5
days post-differentiation. On the day of the experiment, the MEA plates were connected to
a head stage amplifier. FP was acquired at 2 kHz, and all recordings were performed at
37˚C. Signals were recorded for 60 seconds at baseline and 5 minutes after drug
application. All drugs were purchased from Sigma-Aldrich, otherwise stated. Stock
solutions were prepared daily in appropriate solvent and used at desired concentrations
made in RPMI/B27 medium. Data were analyzed by Cardio2D software (version 2.2.2.0,
Multichannel system MCS GmbH). FP durations (FPD) was normalized to beating rate using the
Bazett correction formula (corrected FPD [cFPD]=FPD/3 √ (RR interval)). Drugs
used in pharmacological studies are listed in Table S4 (See Supplementary Online
Information at www.celljournal.org).
Whole cell patch-clamp recording
Action potential (AP) was recorded from spontaneously beating hiPSC-CM using the
current-clamp mode of the whole cell patch-clamp configuration. On differentiation day 30,
beating spheroids were dissociated into single cells by Accutase accompanied by gentle
pipetting. Single beating CM were plated onto ECM-Gel coated glass coverslips and
incubated at 37˚C overnight. Then, the cover slips were transferred to a recording chamber
mounted on the stage of an Olympus inverted microscope (Olympus, Japan). The bath solution
within the chamber contained 135 mM NaCl, 5.4 mM KCl, 10 mM HEPES, 10 mM D-glucose, 1 mM
MgCl, and 1.8 mM CaCl2 and the pH was adjusted to 7.4 using NaOH. Recording
pipettes were pulled from borosilicate glass capillaries (Harvard Apparatus, Holliston,
MD) by a P-97 horizontal puller (Sutter Instrument, Novato) to a tip resistance of 3-6 MΩ.
The pipette solution contained 135 mM KCl, 10 mM NaCl, 1 mM EGTA, 10 mM HEPES, and 5 mM
MgATP, and the pH was adjusted to 7.2 using KOH.Data were acquired using a multiclamp 700B amplifier
(Axon Instruments, Molecular Devices Corp., Union City, CA,
USA), a Digidata 1440 analog-to-digital board and pClamp
10 software (Axon Instruments), at a sampling frequency
of 10 kHz and low-pass filtered at 2 kHz. Data analysis was
performed using Clampfit 10 (Axon Instruments) and Prism
6 (GraphPad Software, La Jolla, CA, USA) software.
Ca+2 imaging
In order to record Ca+2 transients in hiPSC-CM, beating spheroids were
incubated with 1 µM Fura-2 AM (Sigma-Aldrich, USA) for 30 minutes at 37˚C, 30-day
post-differentiation. Then, beating spheroids were washed with RPMI/B27 medium for 15
minutes at 37˚C. Afterwards, Ca+2 imaging was performed using a fluorescent
microscope (IX71, Olympus, Japan) equipped with a DP72 digital camera (Olympus, Japan) and
analyzed in a custom- made Matlab macro. Calcium transient amplitude and calcium transient
duration at 80% decay (CTD80) were calculated. In order to study the Ca+2
content of sarcoplasmic reticulum (SR), rapid puffs of 10 mM caffeine were applied and
Ca+2 release was imaged. Fractional Ca+2 release (FCR) from the
stores was calculated as the ratio of the amplitude of Ca+2 transient to the
amplitude of the caffeine-induced Ca+2 release.
Statistical methods
All data are presented as mean ± SEM from at least three
independent biological replicates for each hiPSC line.
Comparisons were made by analysis of variance (ANOVA,
one-way and two way) or unpaired t test when appropriate,
using GraphPad Prism version 6.01 (GraphPad Software,
La Jolla California, USA) and considered significant when
P<0.05.
The datasets generated during and/or analysed during
the current study are available from the corresponding
author on reasonable request.
Results
Systemic sclerosis fibroblasts were successfully reprogrammed to pluripotency
in vitro
To generate SSc iPSC, primary fibroblasts were obtained from skin biopsy of each
patient following receiving an informed written consent. Cells were reprogrammed with
Yamanaka factors using retroviral vectors. After 20 days, hESC-like colonies were picked
and expanded for characterization (Fig.1A). Both SSc iPSC lines revealed strong ALP
activity (Fig.1A) and expressed major hESC-specific markers (OCT4, NANOG, TRA-1-60, and
TRA-1-81, Fig.1B). Furthermore, a normal karyotype was determined for both SSciPSC lines
(S1- iPS2 and S2-iPS3) indicating chromosomal stability during iPSC generation (Fig.1C).
To further confirm reprogramming to pluripotency, the expression of OCT4
and NANOG was evaluated which revealed that both S1-iPS2 and S2-iPS3
expressed endogenous OCT4 and NANOG (Fig.1D). In
addition, qRT-PCR analysis showed silencing of exogenous genes (OCT4, c-MYC,
KLF4 and SOX2) in derived S1-iPS2 and S2-iPS3 (Fig. S1, See
Supplementary Online Information at www. celljournal.org). Differentiation potency of
S1-iPS2 and S2-iPS3 into embryonic germ layers was evaluated by EB formation. To achieve
that, iPSC were cultured in suspension for 12 days to form EB in the absence of bFGF and
then transferred to ECM Gel-coated dishes for another 8 days. RT-PCR analyses demonstrated
that ectoderm (PAX6 and TAU), mesoderm
(Brachyury) and endoderm (ALB and
FOXA2) specific markers were only expressed in differentiated S1-iPS2
and S2-iPS3but not in undifferentiated state (Fig.1E). Furthermore, spontaneous
differentiation of iPSC lines resulted in the development of ectoderm, mesoderm and
endoderm cells as reflected by upregulation of SOX1/PAX6, MESP1/Brachyury
and FOXA2/AFP genes as specific markers of each germ layer, respectively
(Fig.S2, See Supplementary Online Information at www.celljournal.org). Moreover, SSci PSC
were transplanted into the subrenal capsule of 5-week-old NOD mice. After about 7 weeks,
teratoma was formed, harvested and subjected to immunohistochemistry analyses. Our results
demonstrated the presence of cartilage (mesoderm), gut-like epithelium (endoderm) and
neural rosette (ectoderm) tissues in teratoma which further confirmed stemness of iPSC
(Fig.1F). Altogether, these data showed that SSc fibroblasts were successfully
reprogrammed to pluripotency.
Systemic sclerosis induced pluripotent stem cells were
successfully differentiated into endothelial progenitor
cells
hiPSC lines were differentiated to ECs by a cocktail of growth factors and SMs
(Fig.2A). Cells were collected on days 0, 1, 4, 6 and 8 of differentiation in order to
evaluate the expression of endothelial genes and proteins. The highest level of
Brachyury transcriptional expression was observed on day 1 (Fig.2B).
The expression of KDR was substantially increased on day 6 of
differentiation in iPSC lines (40.3 ± 7, 26.4 ± 8 and 15.9 ± 0.6 fold increase compared to
undifferentiated state in C1-EC, S1-EC and S2-EC, respectively, Fig.S3A, See Supplementary
Online Information at www.celljournal.org). Flow cytometry analyses indicated that almost
30% of cells were KDR-positive (Fig.2C) implicating their identical potential for
endothelial progenitor cells (EPC) generation. Although the percentage of KDR expressing
cells was similar in C1-EC and both SSc iPSC lines-derived EC, the levels of expression
were reduced in SSc-ECs (Fig.S3B, See Supplementary Online Information at www.celljournal.
org).
Fig.2
Differentiation of SSc iPSC toward endothelial lineage. A. A schematic diagram
illustrating the endothelial differentiation protocol in which growth factors and
small molecules were used, B. The relative expression of
Brachyury gene during differentiation as assessed by qRT-PCR,
C. Flow cytometry analysis of KDR expression on differentiation day 6
demonstrated no significant difference between SSc-EC and C1-EC, D.
Similar expression of CD31 at mRNA and E. At protein
levels in iPSC-derived EC, F. qRT-PCR analysis demonstrated that
VE-cadherin was significantly downregulated in SSc-EC compared to
C1-EC. The expression of each gene was normalized against GAPDH. The
relative expression was calculated by ∆∆Ct method (undifferentiated state ‘’D0’’ was
set at 1), G. Expression level of VE-cadherin protein was measured by
flow cytometry, and H. Immunofluorescence staining demonstrated the
expression of vWF, CD31 and VE-cadherin in iPSC-derived EC. Nuclei were counterstained
with DAPI (scale bar: 100 µm). All data are represented as mean ± SEM. Comparisons
were made by one-way and two-way analysis of variance (***; P<0.001). SSc;
Systemic sclerosis, iPSC; Induced pluripotent stem cells, qRT-PCR; Quantitative
real-time polymerase chain reaction, VE; Vascular endothelial, EC; Endothelial cells,
C1-EC; Healthy control iPSC-EC, S1-EC; SSc1 iPS2-EC, and S2-EC; SSc2 iPS3- EC. n≥3
(biological replicate) for all experiments.
KDR-positive cells were sorted on day 6 and cultured in VEGF-A supplemented media on
collagen I-coated plates to confluency (Fig.2A). Expression of CD31
(PECAM-1) as a late endothelial marker was substantially upregulated on
differentiation day 8 (60.5 ± 10, 79.2 ± 11 and 63.4 ± 6 fold increase compared to
undifferentiated state in C1- EC, S1-EC and S2-EC, respectively) which was followed by a
fairly similar protein expression pattern (90.5 ± 1%, 93.5 ± 1% and 87.7 ± 4% in C1-EC,
S1-EC and S2-EC, respectively) (Fig.2D, E). Relative expression of CD31
on differentiation day 8 was similar in iPSC lines-derived EC (Fig.S3B, See Supplementary
Online Information at www.celljournal.org). In contrast, while
VE-cadherin (CD144) expression in C1-EC peaked on
differentiation day 8, neither S1-EC nor S2-EC showed upregulation of this endothelial
specific marker (Fig.2F, G). C1-EC exhibited 87-fold rise in VE-cadherin
expression during differentiation and 91.7% of C1-EC were positive for VE-cadherin.
However, no more than 8.6 and 3.9% of differentiated S1-iPS2 and S2-iPS3 were
CD144+ , respectively. Immunostaining for CD31 and CD144 showed a similar
pattern to that for gene expression and further confirmed the protein expression results
obtained from flow cytometry analyses. Furthermore, ECs derived from both C1-and SSciPSC,
expressed endothelial marker vWF (von Willebrand factor) in a similar manner (Fig.2H). To
evaluate the functional characteristics of differentiated ECs, the ability to uptake
acetylated low-density lipoprotein (AcLDL) as well as tube formation potential was
examined. Both SSc iPSC-derived EC (SSc-EC) revealed strong AcLDL uptake capacity when
incubated with these lipoprotein particles (Fig.3A). However, these ECs failed to form
tubes (Fig.3B). While C1-EC developed vessel-like tubes with around 70 ± 5 tubes/field,
134.3 branch points/field and mean tube area of 0.12 mm2 (Fig.3C-E, respectively), the
number of well-formed tubes were substantially decreased to 10 ± 7 and 13 ± 3 tubes/field
in S1- and S2-EC, respectively (Fig.3C). This characteristic was also projected into a
marked reduction in the number of branch points as well as smaller tube areas when tube
formation ability of SSc-EC was assessed (Fig.3D, E). These results suggested a defective
angiogenic capacity for SSc-EC.
Fig.3
Functional analyses of SSc-EC. A. Immunofluorescence staining of C1-EC, S1-EC and
S2-EC demonstrated DiI-LDL uptake by iPSC-derived EC. Nuclei were counterstained with
DAPI (blue) (scale bar: 50 µm), B. SSc-EC did not form tube-like
structures in vitro (scale bar: 500 µm), C-E. Analyses
of tube-like structures demonstrated that SSc-EC lacked angiogenic properties, and
F. Gene expression analysis in iPSC-derived EC. All data are
represented as mean ± SEM. Comparisons were made by one-way analysis of variance or
unpaired t test when appropriate (* ; P<0.05, * * ; P<0.01, and ***;
P<0.001). SSc; Systemic sclerosis, EC; Endothelial cells, iPSC; Induced
pluripotent stem cells, C1-EC; Healthy control iPSC-EC, S1-EC; SSc1 iPS2-EC, and
S2-EC; SSc2 iPS3-EC. n≥3 (biological replicate) for all experiments.
Characterization of established SSc iPSC. A. Phase contrast microscopy of
established SSc iPSC clones [S1-iPS2 (patient 1) and S2-iPS3 (patient 2)] and ALP
staining of derived iPSC (scale bar: 200 µm), B. Immunofluorescence
staining demonstrated the expression of pluripotency markers (OCT4, NANOG, TRA-1-60
and TRA-1-81) in derived iPSC. Nuclei were counterstained with DAPI (scale bar: 100
µm), C. Both S1-iPS2 and S2-iPS3 lines maintained normal karyotype,
D. qRT-PCR analysis showed endogenous OCT4 and
NANOG expression in SSc iPSC to levels similar to those of healthy
control-iPSC (C1-iPSC) while were silent in the HDF. Fold change was calculated by
∆∆Ct method and expression of each gene was normalized against GAPDH,
E. RT-PCR analyses indicated the expression of differentiation markers
for the three germ layers by EB-mediated differentiation (Diff) in comparison with
undifferentiated state (Un), and F. Tissue morphology of teratoma derived
from SSc iPSC (scale bar: 100 µm). Data are represented as mean ± SEM, n=3 (biological
replicate). SSc; Systemic sclerosis, iPSC; Induced pluripotent stem cells, ALP;
Alkaline phosphatase, qRT-PCR; Quantitative real-time polymerase chain reaction, HDF;
Human dermal fibroblasts, and EB; Embryoid body.Differentiation of SSc iPSC toward endothelial lineage. A. A schematic diagram
illustrating the endothelial differentiation protocol in which growth factors and
small molecules were used, B. The relative expression of
Brachyury gene during differentiation as assessed by qRT-PCR,
C. Flow cytometry analysis of KDR expression on differentiation day 6
demonstrated no significant difference between SSc-EC and C1-EC, D.
Similar expression of CD31 at mRNA and E. At protein
levels in iPSC-derived EC, F. qRT-PCR analysis demonstrated that
VE-cadherin was significantly downregulated in SSc-EC compared to
C1-EC. The expression of each gene was normalized against GAPDH. The
relative expression was calculated by ∆∆Ct method (undifferentiated state ‘’D0’’ was
set at 1), G. Expression level of VE-cadherin protein was measured by
flow cytometry, and H. Immunofluorescence staining demonstrated the
expression of vWF, CD31 and VE-cadherin in iPSC-derived EC. Nuclei were counterstained
with DAPI (scale bar: 100 µm). All data are represented as mean ± SEM. Comparisons
were made by one-way and two-way analysis of variance (***; P<0.001). SSc;
Systemic sclerosis, iPSC; Induced pluripotent stem cells, qRT-PCR; Quantitative
real-time polymerase chain reaction, VE; Vascular endothelial, EC; Endothelial cells,
C1-EC; Healthy control iPSC-EC, S1-EC; SSc1 iPS2-EC, and S2-EC; SSc2 iPS3- EC. n≥3
(biological replicate) for all experiments.Downregulation of VE-cadherin and inability to form tubular network in SSc-derived ECs
led us to examine VE-cadherin signaling and regulation.VE-cadherin/β-catenin signaling
regulates the expression of matrix metalloproteinases (MMPs) in ECs during angiogenesis
(17). The importance of MMPs in angiogenesis as well as possible angiogenesis-related
changes in the expression of MMPs and VE-cadherin, was reported previously (18). In our
in vitro differentiated SSc-ECs, while the expression of
MMP1 was 2.4-fold upregulated in S1- EC, MMP9
expression showed 12-fold decrease compared to C1-EC, suggesting a dysregulation of
MMP1 and MMP9 expression in S1-EC (Fig.3F).
Scleroderma vessels have abnormal ECs which express regulator of G protein signaling 5
(RGS5), a protein associated with vascular rarefaction, but lack normal VE-cadherin
expression (19). Interestingly, relative expression of RGS5 was similar
in C1-and S1-EC characterized in this study (Fig.3F). Moreover, the relative expression of
endothelin 1 (EDN1), which is involved in vascular
remodeling of SSc (20), showed similar patternin S1- and C1-EC (Fig.3F).Multiple mechanisms are involved in regulation of VE-cadherin including mammalian
target of rapamycin (MTOR) and phosphoinositide-3 kinase (PI3K) signaling (21). In order
to address the mechanism involved in the downregulation of VE-cadherin in S1-EC, the
expression of PI3KCA (PI3K catalytic subunit alpha) and MTOR was assessed in iPSC-derived
EC. Transcriptional analyses showed significant upregulation of MTOR and
PI3KCA in S1-EC compared to C1-EC. Furthermore, the expression of
SNAI1, a transcriptional repressor of VE-cadherin, was markedly
increased in SSc-EC, indicating the possible role of SNAI1 in
downregulation of VE-cadherin (Fig.3F).
Systemic sclerosis induced pluripotent stem cells could
generate functional cardiomyocytes
iPSC lines were subjected to cardiomyocyte differentiation in static suspension culture
using a SM-based protocol (Fig.4A) which resulted in generation of spontaneously beating
spheroids on day 7 that expanded to about 90% of spheroids on differentiation day 10. The
ratio of beating spheroids was calculated daily and plotted for all three hiPSC lines
(Fig.4B); this ratio peaked on day 10 (93.6 ± 1, 89.6 ± 0.9 and 90 ± 1.1% for healthy
control iPSC-derived cardiomyocytes [C2-CM], S1-CM and S2-CM, respectively) showing their
similar cardiac differentiation potency. The efficiency of cardiogenic differentiation was
evaluated in C2 and SSc iPSC by assessing the gene and protein expression of cardiac
specific markers (Fig.4C-E). All C2-iPSC, S1-iPS2 and S2-iPS3 derived CM expressed cardiac
specific genes encoding cardiac structural proteins namely; TNNT2
(cardiac type of troponin), MYL2 (myosin light chain 2) and
MYH (myosin heavy chain), encoding calcium handling proteins;
SERCA (sarco/endoplasmic reticulum Ca2+-ATPase),
SLC8A1 (solut carrier family 8 of member A1), CACNA1C
(calcium voltage-gated channel), RYR2 (ryanodine receptor),
TRDN (Triadin) and CASQ (calsequestrin), and encoding
ion channels; KCNH2 (potassium voltage-gated channel). While
MYL2, MYH6 and MYH7 were upregulated in S1-CM, relative
expression of these contractile apparatus-related genes were similar in S2-CM and C2-CM
(Fig.4C). Furthermore, MYH6/MYH7 ratio was decreased by 4- and 2-fold in
S1-CM and S2-CM, respectively compared to C2-CM. While expression of
CASQ2 and KCNH2 was substantially higher in S1-CM,
RYR2 expression was markedly elevated in both S1- and S2-CM. On the
other hand, expression levels of other genes encoding calcium handling proteins
(CACNA1C, TRDN, SERCA, and SLC8A1) were similar in all
three hiPSC-derived CM. Protein expression of cTNT showed a similar pattern to that of its
gene expression as reflected in immunostaining images; also, both SSc and C2 iPSC lines
generated similar abundance of cTNT+ CM (Fig.4D, E). Altogether, these results
indicated that SSc iPSC and healthy control iPSC have the same cardiogenic differentiation
potential.
Fig.4
Generation and characterization of SSc iPSC-derived CM. A. A schematic diagram of
the static suspension culture system used to induce cardiac differentiation of hiPSC
lines. Five days after expansion in hESC medium, hiPSC aggregates (average size, 175 ±
25 μm) were transferred to low-attachment dishes containing differentiation medium and
treated with 12 µM CHIR99021 for 1 day. After 1-day rest, the aggregates were treated
with IWP2, SB431542, and purmorphamine (5 µM each) for 2 days, after which the media
was exchanged every 2-3 days, B. The percentage of beating spheroids over
the experimental period (n=3, biological replicate), C. Expression of
cardiac markers in iPSC-derived CM on differentiation day 30 as measured by qRT-PCR.
Fold change was calculated by ∆∆Ct method and expression of each gene was normalized
against GAPDH (n=3, biological replicate), D. α-actinin
(green) and troponin T (red) immunostaining of iPSC-derived CM on day 30 of cardiac
differentiation. Nuclei were counterstained with DAPI (blue) (scale bar: 50 µm), and
E. Flow cytometry analysis of cTnT+ cells showed same cardiac
differentiation efficiency for SSc iPSC and control iPSC (n=3, biological replicate).
All data are represented as mean ± SEM. Comparisons were made by one-way analysis of
variance or unpaired t test when appropriate (* ; P<0.05 and * *; P<0.01
shows significant differences versus healthy control). SSc; Systemic sclerosis, iPSC;
Induced pluripotent stem cells, CM; Cardiomyocytes, hiPSC; Human induced pluripotent
stem cells, hESC; Human embryonic stem cells, qRT-PCR; Quantitative real-time
polymerase chain reaction,C2-CM; Healthy control iPSC-CM, S1-CM; SSc1 iPS2-CM, and
S2-CM; SSc2 iPS3- CM.
Systemic sclerosis induced pluripotent stem cells-derived
CM revealed normal excitation-contraction coupling
To evaluate the functional properties of differentiated CM, two components of
excitation-contraction coupling were studied. FPs generated by spontaneously beating
spheroids were recorded to study the electrophysiological properties of SSc and C2-CM
(Fig.5A). All differentiated CM derived from either SSc iPSC or control iPSC, showed a
normal beating frequency of about 65 beats per minute (bpm) (Fig.5B). FP duration (FPD)
which provides information on the repolarization phase of cardiomyocytes’ excitation and
has been reported to be well correlated with AP duration obtained from a single
cardiomyocyte (22), did not differ between SSc-and C2-derived cardiac spheroids (Fig.5C).
Furthermore, single spontaneously beating CM were evaluated for their AP. Two types of AP,
one specific for working CM and the other specific for nodal-like cells, were observed in
C2-CM, S1-CM and S2-CM (Fig.5D). Various AP parameters such as maximal diastolic potential
(MDP), upstroke velocity (Vmax) and AP duration at different time-points of
repolarization (APDx) as well as APD90/ APD50 ratio were
used for AP classification (23). Analysis of AP parameters showed that working CM were
highly frequent in both C2- and SSc iPSC-derived CM (Fig.5E-K). Electrophysiological
characteristics of iPSC-derived CM are summarized in Tables S5 and S6 (See Supplementary
Online Information at www.celljournal.org).
Fig.5
Electrophysiological properties of SSc iPSC-derived CM. A. Representative
extracellular FP recorded from iPSC-derived beating spheroids using MEA at baseline,
B, C. Electrophysiological features of cardiomyocytes as assessed by
MEA revealed similarities in spontaneous beating rate (bpm) and FPD between SSc
iPSC-derived CM and C2-CM, D. Representative AP recorded from single CM
using whole-cell mode of patch-clamp technique, and E-K. Statistical
analyses of action potential characteristics showed no significant differences between
C2- and SSc iPSC-derived CM. All data are presented as mean ± SEM. Comparisons were
made by one-way analysis of variance (ANOVA). SSc; Systemic sclerosis, iPSC; Induced
pluripotent stem cells, CM; Cardiomyocytes, FP; Field potential, MEA; Multielectrode
array, FPD; Field potential duration, AP; Action potential, ISI; Inter spike Interval,
FPA; Field potential amplitude, MDP; Maximal diastolic potential, APA; Action
potential amplitude, Vmax; Maximal upstroke velocity, APD 30-70; Action
potential duration measured at 30-90% of repolarization, C2-CM; Healthy control
iPSC-CM, S1-CM; SSc1 iPS2-CM, and S2-CM; SSc2 iPS3- CM. (n≥7 in MEA experiments and n
≥ 18 in patch-clamp experiments).
Ca2+ transients as another component of excitation-contraction coupling was
characterized in C2-CM, S1-CM and S2-CM. Ca2+ transient amplitude (Fig. S4A,B,
See Supplementary Online Information at www.celljournal.org) and CTD80 did not
significantly differ between patient-specific and healthy CM (Fig. S4C, See Supplementary
Online Information at www. celljournal.org). Furthermore, fractional Ca2+
release which represents the ratio of active intracellular Ca2+ bulk to whole
intracellular Ca2+, did not vary betweenC1-CM, S1-CM and S2-CM (Fig.S4D, See
Supplementary Online Information at www.celljournal.org). Fractional Ca2+
release is basically defined as the ratio of the excitation-induced Ca2+
release to caffeine-induced Ca2+ release which depletes all intracellular
Ca2+ stores.Functional analyses of SSc-EC. A. Immunofluorescence staining of C1-EC, S1-EC and
S2-EC demonstrated DiI-LDL uptake by iPSC-derived EC. Nuclei were counterstained with
DAPI (blue) (scale bar: 50 µm), B. SSc-EC did not form tube-like
structures in vitro (scale bar: 500 µm), C-E. Analyses
of tube-like structures demonstrated that SSc-EC lacked angiogenic properties, and
F. Gene expression analysis in iPSC-derived EC. All data are
represented as mean ± SEM. Comparisons were made by one-way analysis of variance or
unpaired t test when appropriate (* ; P<0.05, * * ; P<0.01, and ***;
P<0.001). SSc; Systemic sclerosis, EC; Endothelial cells, iPSC; Induced
pluripotent stem cells, C1-EC; Healthy control iPSC-EC, S1-EC; SSc1 iPS2-EC, and
S2-EC; SSc2 iPS3-EC. n≥3 (biological replicate) for all experiments.Generation and characterization of SSc iPSC-derived CM. A. A schematic diagram of
the static suspension culture system used to induce cardiac differentiation of hiPSC
lines. Five days after expansion in hESC medium, hiPSC aggregates (average size, 175 ±
25 μm) were transferred to low-attachment dishes containing differentiation medium and
treated with 12 µM CHIR99021 for 1 day. After 1-day rest, the aggregates were treated
with IWP2, SB431542, and purmorphamine (5 µM each) for 2 days, after which the media
was exchanged every 2-3 days, B. The percentage of beating spheroids over
the experimental period (n=3, biological replicate), C. Expression of
cardiac markers in iPSC-derived CM on differentiation day 30 as measured by qRT-PCR.
Fold change was calculated by ∆∆Ct method and expression of each gene was normalized
against GAPDH (n=3, biological replicate), D. α-actinin
(green) and troponin T (red) immunostaining of iPSC-derived CM on day 30 of cardiac
differentiation. Nuclei were counterstained with DAPI (blue) (scale bar: 50 µm), and
E. Flow cytometry analysis of cTnT+ cells showed same cardiac
differentiation efficiency for SSc iPSC and control iPSC (n=3, biological replicate).
All data are represented as mean ± SEM. Comparisons were made by one-way analysis of
variance or unpaired t test when appropriate (* ; P<0.05 and * *; P<0.01
shows significant differences versus healthy control). SSc; Systemic sclerosis, iPSC;
Induced pluripotent stem cells, CM; Cardiomyocytes, hiPSC; Human induced pluripotent
stem cells, hESC; Human embryonic stem cells, qRT-PCR; Quantitative real-time
polymerase chain reaction,C2-CM; Healthy control iPSC-CM, S1-CM; SSc1 iPS2-CM, and
S2-CM; SSc2 iPS3- CM.Electrophysiological properties of SSc iPSC-derived CM. A. Representative
extracellular FP recorded from iPSC-derived beating spheroids using MEA at baseline,
B, C. Electrophysiological features of cardiomyocytes as assessed by
MEA revealed similarities in spontaneous beating rate (bpm) and FPD between SSc
iPSC-derived CM and C2-CM, D. Representative AP recorded from single CM
using whole-cell mode of patch-clamp technique, and E-K. Statistical
analyses of action potential characteristics showed no significant differences between
C2- and SSc iPSC-derived CM. All data are presented as mean ± SEM. Comparisons were
made by one-way analysis of variance (ANOVA). SSc; Systemic sclerosis, iPSC; Induced
pluripotent stem cells, CM; Cardiomyocytes, FP; Field potential, MEA; Multielectrode
array, FPD; Field potential duration, AP; Action potential, ISI; Inter spike Interval,
FPA; Field potential amplitude, MDP; Maximal diastolic potential, APA; Action
potential amplitude, Vmax; Maximal upstroke velocity, APD 30-70; Action
potential duration measured at 30-90% of repolarization, C2-CM; Healthy control
iPSC-CM, S1-CM; SSc1 iPS2-CM, and S2-CM; SSc2 iPS3- CM. (n≥7 in MEA experiments and n
≥ 18 in patch-clamp experiments).
Systemic sclerosis induced pluripotent stem cells-derived CM were responsive to
cardioactive drugs
Heart rate and contractility are regulated by the autonomic nervous system (22). To
study the responsiveness of differentiated CM to neurohormonal regulation, the effects of
a β-stimulant and a β-blocker agent (isoproterenol and propranolol, respectively) on
C2-CM, S1-CM and S2-CM were assessed. Baseline extracellular FP was recorded for each
spontaneously beating spheroid mounted on the electrodes of a MEA plate followed by
recordings in the presence of serial concentrations of isoproterenol (Iso). The FP
recording was performed 300 seconds after Iso application and antagonized by serial
concentrations of propranolol (Pro). Iso and Pro concentrations were chosen based on
previous studies (22). β1 -adrenergic stimulation by Iso substantially
increased the spontaneous beating frequencies of iPSC-derived CM (5 µM Iso vs. baseline;
1.4-1.8, and 1.7 fold in C2- CM-S1, CM and S2-CM-respectively) which were antagonized by
Pro as reflected by substantial reduction of beating rates to values approaching baseline
frequencies. Furthermore, Iso administration caused significant shortening of FPD and cFPD
which were reversed by Pro treatment (Fig.6A, B). Thus, SSc iPSC-derived CM responded to
β-adrenergic agonist and antagonist in a similar manner to C2-CM. Also, the effect of
sotalol as a cardioactive drug that blocks hERG channel was assessed on SSc iPSC-derived
CM. Serial concentrations of sotalol (100 nM, 10 µM, 30 µM, 100 µM, and 500 µM) caused a
gradual reduction of beating frequencies which accompanied by significant
concentration-dependent FPD prolongation (Fig.6C, D). Verapamil as an L-type calcium
channel blocker, was also added to CM differentiated from SSc iPSC. While serial
concentrations of verapamil (50, 100, and 200 nM) induced a dose-dependent reduction of
beating frequencies in C2-CM, it produced no effects on beating cycles of S1- and S2-CM.
However, verapamil at concentrations ≥ 100 nM caused a significant reduction of FPD and
cFPD in both patient-specific and control iPSC-derived CM (Fig.6E, F). Drug concentrations
were chosen based on pervious works (24). Altogether, these results indicated that SSc
iPSC-derived CM, are responsive to some important cardioactive drugs.
Fig.6
Response of SSc iPSC-derived CM to cardioactive drugs. A. Representative MEA traces
showing FP shortenings induced by Iso treatment followed by FP prolongation after Pro
administration, B. Iso significantly increased the beating frequency of
CM derived from both SSc and control iPSC, but this increment was reversed by Pro. Iso
reduced cFPD which was prolonged by Pro in hiPSC-derived CM, C. The
prolongation of FP caused by sotalol, D. Reducing effect of sotalol on
beating frequency. Treatment with sotalol prolonged the FPD and cFPD, E.
The shortening of FP caused by verapamil, and F. Verapamil reduced beating rate of
C2-CM and shortened the FPD and cFPD in iPSC-derived CM. All data are represented as
mean ± SEM. Comparisons were made by one-way analysis of variance (ANOVA) or unpaired
t test when appropriate (n ≥ 3, biological replicate). *; Shows significant
differences of C2-CM, #; Significant differences of S1-CM and +; Significant
differences of S2-CM following drug application (+, #, *; P<0.05, ##, ++, **;
P<0.01, ###, +++, ***; P<0.001), SSc; Systemic sclerosis, iPSC; Induced
pluripotent stem cells, MEA; Multielectrode array, FP; Field potential, CM;
Cardiomycyte, C2-CM; Healthy control iPSC-CM, S1-CM; SSc1 iPS2-CM, S2-CM; SSc2 iPS3-
CM, Iso; Isoproterenol, Pro; Propranolol, bpm; Beats per minute, FPD; Field potential
duration, and cFPD; Corrected FPD (corrected according to the Bazett Formula).
Response of SSc iPSC-derived CM to cardioactive drugs. A. Representative MEA traces
showing FP shortenings induced by Iso treatment followed by FP prolongation after Pro
administration, B. Iso significantly increased the beating frequency of
CM derived from both SSc and control iPSC, but this increment was reversed by Pro. Iso
reduced cFPD which was prolonged by Pro in hiPSC-derived CM, C. The
prolongation of FP caused by sotalol, D. Reducing effect of sotalol on
beating frequency. Treatment with sotalol prolonged the FPD and cFPD, E.
The shortening of FP caused by verapamil, and F. Verapamil reduced beating rate of
C2-CM and shortened the FPD and cFPD in iPSC-derived CM. All data are represented as
mean ± SEM. Comparisons were made by one-way analysis of variance (ANOVA) or unpaired
t test when appropriate (n ≥ 3, biological replicate). *; Shows significant
differences of C2-CM, #; Significant differences of S1-CM and +; Significant
differences of S2-CM following drug application (+, #, *; P<0.05, ##, ++, **;
P<0.01, ###, +++, ***; P<0.001), SSc; Systemic sclerosis, iPSC; Induced
pluripotent stem cells, MEA; Multielectrode array, FP; Field potential, CM;
Cardiomycyte, C2-CM; Healthy control iPSC-CM, S1-CM; SSc1 iPS2-CM, S2-CM; SSc2 iPS3-
CM, Iso; Isoproterenol, Pro; Propranolol, bpm; Beats per minute, FPD; Field potential
duration, and cFPD; Corrected FPD (corrected according to the Bazett Formula).
Discussion
Here, we reported the generation of iPSC lines from two patients with SSc and their
endothelial and cardiac differentiation. ECs were successfully derived from iPSC using a
cocktail of growth factors and SMs that target signaling pathways involved in vascular
system development, in vivo. Although SSc iPSC possessed the same
pluripotency characteristics as their healthy counterparts, they showed different EC
differentiation potentials. Furthermore, we found that angiogenic activity was significantly
reduced in SSc-EC. Although there were no alterations at the primary stages of endothelial
differentiation as reflected in similar expression of KDR, maturation phase of ECs was
altered as presented in downregulation of VE-cadherin and loss of tube formation. Consistent
with our results, Fleming et al. (25) stained endothelium and showed loss of VE-cadherin
from some vessels of SSc patients. In contrast, Wang et al. (26) did not observe alterations
in VE-cadherin protein expression in SSc iPSC-derived EC. Moreover study, Cipriani et al.
(27) characterized CD31+ sorted EC isolated from SSc patients and did not report
impaired VE-cadherin expression.The important role of VE-cadherin in ECs’ tube
formation is known so as anti-VE cadherin significantly
decreased the number of tube structures in human umbilical
vein ECs (HUVEC) (28). Importantly, VE-cadherin
knockout resulted in defective EC maturation in animal
models (29). Furthermore, Montero-Balaguer et al. (30)
studied VE-cadherin function by making a knockdown
of VE-cadherin in zebrafish using morpholino. They
showed that partial VE-cadherin inactivation leads to
vascular fragility, thus total amount of expressed protein
is essential for vascular stability.The role of MTOR in vascular development was
previously reported (31). Bieri et al. (21) reported the
regulatory effect of MTOR and PI3K signaling in VE-cadherin expression of HUVEC. Despite their report, we
did not observe a similar pattern for PI3K, MTOR and VE-cadherin expression in SSc-EC suggesting there might be
another mechanism involved in VE-cadherin regulation
in SSc-ECs. It should be noted that in fibroblasts obtained
from SSc patients, the expression of MTOR is elevated
and it is involved in fibrotic response. Indeed, blockade of
MTOR pathway is being studied as a potential therapeutic
approach for scleroderma (32, 33).Multiple mechanisms are involved in VE-cadherin
regulation including Twist/Slug/Snail family which are
transcriptional repressors of VE-cadherin gene (34).
Lopez et al. (34) investigated the cause of VE-cadherin
downregulation in ECs exposed to breast cancer cells-conditioned media and found direct repression of VE-cadherin promoter by Twist/Slug/Snail family. In the
current study, we also observed upregulation of snail1
which might be one of the regulatory mechanisms under
lying VE-cadherin downregulation in SSc-EC.Absence of VE-cadherin expression and subsequent
defective angiogenic activity of SSc-EC motivated us
to assess the effect of VE-cadherin signaling on MMPs
expression, which play multiple roles in angiogenesis (35).
Kiran et al. (18) reported a reciprocal relationship between VE-cadherin and MMPs during angiogenesis. There are
conflicting data on MMPs expression in scleroderma.
While some researchers reported downregulation of MMP1
in scleroderma patients with increases in the levels of tissue
inhibitor of MMP (TIMPs) (36), other studies reported the
increased expression of MMP1 in SSc fibroblasts compared
to healthy fibroblasts (37). Moreover, Kim et al. (38)
investigated the expression of MMP9 in 42 SSc patients
and observed elevated levels of MMP9. In contrast, Fuzii
et al. (39) found decreased expression of MMP9 in dermal
fibroblasts of SSc patients. In the present study, we also
observed alterations in MMP1 and MMP9 expression in
patients’ iPSC-derived EC; however, no reciprocal relation
between MMP9 and VE-cadherin expression was found.As majority of SSc patients suffer from cardiac
involvements (6), we also investigated the cardiac
differentiation of SSc iPSC and found similar cardiogenic
potential when comparing these cells and the healthy
control iPSC. A substantial percentage of differentiated
CM was positive for the cardiac marker cTNT, in all three
hiPSC-derived CM indicating the successful cardiac
differentiation of SSc iPSC. The time course required
for generation of beating CM from SSc iPSC and the
efficiency of cardiogenesis were similar to those observed
for healthy control. A similar pattern for cardiac specific
markers and ion channels expression was observed in SSc
iPSC-derived CM and C2-CM. Also, key components
of the excitation-contraction complex were similarly
expressed in patients and healthy differentiated CM.
Notably, the expression level of MYH6, MYH7 and MYL2
was increased in S1-CM and the MYH6/MYH7 ratio was
lower in both patient-derived CM compared to C2-CM
which may indicate more mature phenotype of SSc iPSC-derived CM; however, the similar functional properties
were found in all cardiomyocytes. SSc-derived CM also
exhibited functional ion channels resulting in appropriate
response to pharmacologically active compounds.
Conclusion
The present study reports the successful differentiation
of SSc iPSC into endothelial and functional cardiac cells
that would provide a unique opportunity for mechanistic
studies of scleroderma pathogenesis and possible targeted
drug discovery.
Authors: Yannick Allanore; Robert Simms; Oliver Distler; Maria Trojanowska; Janet Pope; Christopher P Denton; John Varga Journal: Nat Rev Dis Primers Date: 2015-04-23 Impact factor: 52.329
Authors: Christoph Patsch; Ludivine Challet-Meylan; Eva C Thoma; Eduard Urich; Tobias Heckel; John F O'Sullivan; Stephanie J Grainger; Friedrich G Kapp; Lin Sun; Klaus Christensen; Yulei Xia; Mary H C Florido; Wei He; Wei Pan; Michael Prummer; Curtis R Warren; Roland Jakob-Roetne; Ulrich Certa; Ravi Jagasia; Per-Ola Freskgård; Isaac Adatto; Dorothee Kling; Paul Huang; Leonard I Zon; Elliot L Chaikof; Robert E Gerszten; Martin Graf; Roberto Iacone; Chad A Cowan Journal: Nat Cell Biol Date: 2015-07-27 Impact factor: 28.824